A New Frontier in
Immunomodulatory Therapeutics
CSA BioTech is developing Ceragenins—powerful, first-in-class small molecules delivering broad-spectrum protection against the drug-resistant infections threatening global health.
Antimicrobial Resistance is a Critical Threat
The World Health Organization has identified antimicrobial resistance as one of the greatest threats to global health, comparable to climate change in potential impact.
Caused by antimicrobial resistance worldwide
If AMR goes unchecked
Drug-resistant infections cost globally
CSA BioTech's Ceragenin technology offers a novel approach to combating drug-resistant infections.
Ceragenins: A New Class of Antimicrobials
Discovered at Brigham Young University by Dr. Paul B. Savage, Ceragenins mimic the body's natural antimicrobial peptides.
Mechanism of Action
Ceragenins are cationic steroid antimicrobials that mimic the body's natural defense peptides, providing rapid, broad-spectrum protection.
Key Properties
- Broad-spectrum activity
- Works in seconds
- Extended protection
- Non-toxic & safe
- No resistance
Rapid Action
Time to begin pathogen membrane disruption
Effective Against Drug-Resistant Pathogens
Proven efficacy in research studies
Our Pipeline
CSA-144 in multiple formulations targeting various therapeutic areas across clinical development stages.
Let's Work Together
Join us in the fight against antimicrobial resistance. We're actively seeking partners, collaborators, and distributors.
Partner With Us
Explore licensing opportunities and strategic partnerships to bring Ceragenin technology to new markets.
Discuss PartnershipResearch Collaboration
Join our network of academic and industry partners advancing antimicrobial research.
Start CollaborationGeneral Inquiries
Have questions about our technology or therapeutic pipeline? We'd love to hear from you.
Get in TouchReady to Combat Antimicrobial Resistance?
Our team is ready to discuss how Ceragenin technology can address your specific antimicrobial challenges.